Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …

Hospitalized patients with acute medical conditions are at significant risk of venous
thromboembolism (VTE): approximately 10–30% of general medical patients may develop …

Venous thromboembolism (VTE) is often asymptomatic, misdiagnosed, and unrecognized at
death, and there is a lack of routine postmortem examinations. These factors are thought to …

Background—Considerable variability exists in the use of pharmacological
thromboprophylaxis among acutely ill medical patients, partly because clinically relevant …

Background Venous thromboembolic disease has been extensively studied in surgical
patients. The benefit of thromboprophylaxis is now generally accepted, but it is medical …

Background Information about the variation in the risk for venous thromboembolism (VTE)
and in prophylaxis practices around the world is scarce. The ENDORSE (Epidemiologic …

Objective To determine the efficacy and safety of the anticoagulant fondaparinux in older
acute medical inpatients at moderate to high risk of venous thromboembolism. Design …

Background Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy
protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers …

Background Abdominal surgery for cancer carries a high risk of venous thromboembolism,
but the optimal duration of postoperative thromboprophylaxis is unknown. Methods We …

Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …